Advertisement

Chinese Journal of Integrative Medicine

, Volume 25, Issue 1, pp 51–58 | Cite as

Protective Effect of Ganshuang Granules (肝爽颗粒) on Liver Cirrhosis by Suppressing Regulatory T Cells in Mouse Model

  • Yan-min Liu
  • Hong-bo Shi
  • Yi-rong Liu
  • Hong-lin Shi
  • Feng Ren
  • Yu Chen
  • De-xi Chen
  • Jin-li Lou
  • Zhong-ping DuanEmail author
Original Article
  • 87 Downloads

Abstract

Objective

To investigate the potential antifibrotic mechanisms of Chinese medicine Ganshuang Granules (肝爽颗粒, GSG) and to provide clinical therapeutic evidence of its effects.

Methods

A cirrhotic mouse model was established by intraperitoneally injecting a mixture of CCl4 (40%) and oil (60%) at 0.2 mL per 100 g of body weight twice a week for 12 weeks. After 12-week modeling, GSG was intragastric administrated to the mice for 2 weeks, and the mice were divided into low-, medium- and high-dose groups at doses of 1, 2 and 4 g/(kg·day), respectively. Liver morphology changes were observed using Masson's trichrome staining and B-ultrasound. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and hyaluronic acid (HA) in serum were detected using an automatic biochemistry analyzer. The expressions of desmin, smooth muscle actin (SMA) and Foxp3 in liver were detected by immunoflfluorescence. The regulatory T cell (Treg) frequency was determined through flflow cytometry analysis. Collagen-I, SMA, IL-6, tumor necrosis factor α (TNF-α), interleukin (IL)-1β and transforming growth factor β1 (TGF-β1) expression levels were measured using quantitative polymerase chain reaction (qPCR).

Results

Masson's staining result showed fewer pseudolobule structures and fibrous connective tissue in the GSG-treatment groups than in the spontaneous recovery group. Ultrasonography showed that GSG treatment reduced the number of punctate hyperechoic lesions in mice cirrhotic livers. The serum ALT, AST, HA levels were significantly ameliorated by GSG treatment (ALT: F=8.104, P=0.000; AST: F=7.078, P=0.002; and HA: F=7.621, P=0.001). The expression levels of collagen-I and SMA in the cirrhotic livers were also attenuated by GSG treatment (collagen-I: F=3.938, P=0.011; SMA: F=4.115, P=0.009). Tregs, which were elevated in the fibrotic livers, were suppressed by GSG treatment (F=8.268, P=0.001). The expressions of IL-6, TNF-α and IL-1β increased, and TGF-β levels decreased in the cirrhotic livers after GSG treatment (IL-6: F=5.457, P=0.004; TNF-α: F=6.023, P=0.002; IL-1β: F=6.658, P=0.001; and TGF-β1: F=11.239, P=0.000).

Conclusions

GSG promoted the resolution/regression of cirrhosis and restored liver functions in part by suppressing Treg cell differentiation, which may be mediated by hepatic stellate cells.

Keywords

Ganshuang Granules liver cirrhosis regulatory T cell hepatic stellate cell Chinese medicine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Talwalkar JA, Kamath PS. Influence of recent advances in medical management on clinical outcome of cirrhosis. Mayo Clin Proc 2005;80:1501–1508.CrossRefGoogle Scholar
  2. 2.
    Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy? Hepatology 2006;43(2 Suppl 1):S82–S88.CrossRefGoogle Scholar
  3. 3.
    Wang YD, Han T, He JR. Research progress of chronic liver fibrosis treatment with extract from traditional Chinese medicine. Med Recapitul (Chin) 2012;124:4228–4231.Google Scholar
  4. 4.
    Xie JR, Zhu Y, Zhu WR, Wang JB. Research progress of antifibrotic mechanism of traditional Chinese medicine. Inf Tradit Chin Med (Chin) 2011;28:147–149.Google Scholar
  5. 5.
    Zhang QH, Zhang CR. The effect of GSG on fibrotic marker and liver function in patients with chronic hepatitis B. Guangdong Med J (Chin) 2011;32:118–119.Google Scholar
  6. 6.
    Yue LP, Ma H, Jia JD. Effects of Ganshuang Granules on gene and protein expression of collagen I, collagenII and tissue inhibitor of metalloprotenase1 in HSC-T6 cells. Chin J Integr Tradit West Med Liver Dis (Chin) 2007;17(2):85–87.Google Scholar
  7. 7.
    Dunham RM, Thapa M, Velazquez VM, Elrod EJ, Denning TL, Pulendran B, et al. Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J Immunol 2013;190:2009–2016.CrossRefGoogle Scholar
  8. 8.
    Tu CT, Wang JY. Recent advances in our understanding of the molecular mechanisms of liver fibrosis. Chin J Hepatol (Chin) 2014;22:5–8.Google Scholar
  9. 9.
    Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor c in hepatic stellate cells for their antifibrotic effect. Hepatology 2012;55:1271–1281.CrossRefGoogle Scholar
  10. 10.
    Asahina K, Tsai SY, Li P, Ishii M, Maxson RE Jr, Sucov HM, et al. Mesenchymal origin of hepatic stellate cells, submesothelial cells and perivascular mesenchymal cells during mouse liver development. Hepatology 2009;49:998–1011.CrossRefGoogle Scholar
  11. 11.
    Li Y, Wang J, Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelialmesenchymal transition in liver injury. Proc Natl Acad Sci 2013;110:2324–2329.CrossRefGoogle Scholar
  12. 12.
    Tsukamoto H, Zhu NL, Wang J, Asahina K, Machida K. Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol 2012;27(Suppl 2):S94–S98.CrossRefGoogle Scholar
  13. 13.
    Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013;3:1473–1492.CrossRefGoogle Scholar
  14. 14.
    Friedman, SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125–172.CrossRefGoogle Scholar
  15. 15.
    Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol 2007;293:G809–G816.CrossRefGoogle Scholar
  16. 16.
    Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007;8:1086–1094.CrossRefGoogle Scholar
  17. 17.
    Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic aciddependent mechanism. J Exp Med 2007;204:1757–1764.CrossRefGoogle Scholar
  18. 18.
    Huang CH, Jeng WJ, Ho YP, Teng W, Chen WT, Chen YC, et al. Increased regulatory T cells in patients with liver cirrhosis correlated with hyperbilirubinemia and predict bacterial complications. J Gastroenterol Hepatol 2014;30:775–783.CrossRefGoogle Scholar
  19. 19.
    Li J, Jia M, Liu Y, She W, Li L, Wang J, et al. Telbivudine therapy may shape CD4+ T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. Liver Int 2015;35:834–845.CrossRefGoogle Scholar
  20. 20.
    Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010;329:849–853.CrossRefGoogle Scholar
  21. 21.
    Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 2007;204:1775–1785.CrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2015

Authors and Affiliations

  • Yan-min Liu
    • 1
  • Hong-bo Shi
    • 1
    • 2
  • Yi-rong Liu
    • 3
  • Hong-lin Shi
    • 1
    • 2
  • Feng Ren
    • 1
    • 2
  • Yu Chen
    • 4
  • De-xi Chen
    • 1
    • 2
  • Jin-li Lou
    • 5
  • Zhong-ping Duan
    • 4
    Email author
  1. 1.Department of Liver Diseases Immunology, Beijing Youan HospitalCapital Medical UniversityBeijingChina
  2. 2.Beijing Institute of Hepatology, Beijing Youan HospitalCapital Medical UniversityBeijingChina
  3. 3.Department of Toxic Hepatic Disease, Beijing Youan HospitalCapital Medical UniversityBeijingChina
  4. 4.Artifical Liver Center, Beijing Youan HospitalCapital Medical UniversityBeijingChina
  5. 5.Clinical Laboratory Center, Beijing Youan HospitalCapital Medical UniversityBeijingChina

Personalised recommendations